KOL Insight Archives | Page 14 of 15 | Report Store

Biosimilars and Reimbursement KOL Interview

$599.00

Topics: Biosimilars and Reimbursement

Physician Information

Specialty: Specialty Pharmaceuticals

Location: Alexandria, VA

July 31, 2015

Find out more

ADPD Alzheimer’s Disease Pulse

$599.00

Overview We performed a 5-question survey of 25 neurologists in the US to gauge current familiarity with Alzheimer’s Disease (AD) biomarkers and drugs in clinical development for disease modification. Drugs covered include: BIIB037/BART (BIIB), Solanezumab (LLY), Pioglitazone (Takeda), BAN2401 (ESALY/BIIB), MK-8931 (MRK).

March 19, 2015

Find out more

2015 Post-AAIC KOL Interview

$599.00

Following the 2015 Alzheimer’s Association International Conference (AAIC), we interviewed an Alzheimer’s Disease expert on his opinion of the data presentations and the future of Alzheimer’s Disease treatment.

August 1, 2015

Find out more

Datamonitor Healthcare HIV KOL Interview – Germany

$599.00

A German key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Find out more

Acne Prescribing Practices Pulse Survey

$599.00

We performed a survey of 10 dermatologists currently practicing in the US to gauge

prescribing practices for the treatment of acne.

November 29, 2016

Find out more

Acute Lymphocytic Leukemia KOL Interview

$599.00

[Newer treatments] are definitely being used in the relapse population, and that’s where they made their mark like most other investigational agents for other cancers. I think the issue is that the response rate with initial induction therapy is so high. Whether or not there is going to be a maintenance-type study strategy, that’s a question with some of these therapies that are relatively low toxicity, but when you have a complete remission rate of 90-95%, and ALL’s not the most common disease – it’s a pretty rare cancer actually – that it’s going to be difficult to do large studies for indications in the randomized setting.

February 9, 2016

Find out more

Multiple Myeloma KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and critical unmet needs are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

May 15, 2020

Find out more

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #1

$599.00

This interview covers hepatocellular carcinoma treatment trends in the US. We discuss current treatment options including the recently approved Keytruda and Lenvima. Also disused are Phase III pipeline therapies Imfinzi and Tecentriq for the first-line setting, along with the potential of PD-1/PD-L1 therapies in the adjuvant setting.

February 6, 2019

Find out more

Palbociclib for Breast Cancer

$89.00

Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer

February 1, 2014

Find out more

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

December 22, 2021

Find out more

Pulmonary Hypertension KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Letairis, Opsumit, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.

July 21, 2022

Find out more

Biomedtracker Diabetic Nephropathy/Diabetic Kidney Disease KOL Interview

$599.00

Biomedtracker interviewed a nephrologist based in the US Midwest to determine his views on the drugs in development for diabetic nephropathy/diabetic kidney disease.

May 13, 2016

Find out more

Major Depressive Disorder KOL Interview – UK

$599.00

A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and post-partum depression are covered, with particular focus on Johnson & Johnson’s esketamine.

December 19, 2018

Find out more

Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK

$599.00

An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.

November 19, 2018

Find out more

Rheumatoid Arthritis KOL Interview – California, US

$599.00

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

July 31, 2019

Find out more